The FDA has approved a new noninvasive stereotactic radiotherapy system to treat cancer in breast tissue.
Indications: The GammaPod system is intended for use in the noninvasive stereotactic delivery of a radiation dose to a portion of the breast in conjunction with breast conserving treatment.
Administration: The system uses thousands of focused beams of radiation from 36 rotating radioactive Cobalt-60 sources in combination with a 2-layer, vacuum-assisted cup that immobilizes the breast to achieve a more accurate delivery of radiation.
Efficacy and safety: Approval is based on a study of 17 individuals that showed the prescribed dose was delivered to the breast tumor with minimal radiation-induced side effects such as skin redness or erythema.
FDA clears stereotactic radiotherapy system for use in treating breast cancer [news release]. Silver Spring, MD: FDA. December 22, 2017. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm590313.htm... Accessed December 31, 2017.